Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Helix Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. Each action is associated with a distinct examiner, while the matters span 5 distinct art units. This structure indicates that examiner-specific repetition is limited, although some technical classifications contain more than one pending matter.
EZEWOKO, MICHAEL I is the busiest examiner, with 1 pending matter. No examiner has a larger recorded cluster, so the profile calls for matter-by-matter prosecution review rather than concentrated examiner management. Art-unit organization can still help identify recurring technical questions within the biotechnology and pharmaceutical portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 6 (86%) |
| §103 only | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EZEWOKO, MICHAEL I | 1 | 61.8% | +50.8% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +47.5% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
| WISE, OLIVIA M. | 1 | 33.9% | +29.9% |
| HILL, GRACELYN MARKHAM | 1 | 50.0% | +0.0% |
| CLOW, LORI A | 1 | 64.2% | +28.5% |
| ELKINS, BLAKE HARRISON | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18244592 | ENRICHMENT OF GENETIC MATERIAL WITH UPSCALED COT-1 DNA QUANTITIES | PHAM, KHAI QUYNH TIEN | 8d overdue |
| 19362171 | SYSTEMS AND METHODS FOR PROVIDING TEST RESULTS OF GENE SEQUENCING DATA ON A RECURRING BASIS | EZEWOKO, MICHAEL I | — |
| 18470759 | POLYCYSTIC KIDNEY DISEASE DIAGNOSIS AND TREATMENT BASED ON DETECTION OF PKD1/PKD2 VARIANTS | SITTON, JEHANNE SOUAYA | — |
| 18141009 | GENETIC SCREENING TO DETERMINE HEALTH RISKS ASSOCIATED WITH INTERACTING PHENOTYPES | WISE, OLIVIA M. | — |
| 18136670 | REANALYSIS BASED ON VERSION MANAGEMENT | HILL, GRACELYN MARKHAM | — |
| 18124670 | MITOCHONDRIAL PROBES FOR ENDOGENOUS CONTROL AND CONTAMINATION DETECTION | CLOW, LORI A | — |
| 18102202 | DIFFERENTIATION OF COINFECTION FROM CONTAMINATION WITHIN GENETIC SAMPLES | ELKINS, BLAKE HARRISON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19362171 | SYSTEMS AND METHODS FOR PROVIDING TEST RESULTS OF GENE SEQUENCING DATA ON A RECURRING BASIS | EZEWOKO, MICHAEL I | — |
| 18470759 | POLYCYSTIC KIDNEY DISEASE DIAGNOSIS AND TREATMENT BASED ON DETECTION OF PKD1/PKD2 VARIANTS | SITTON, JEHANNE SOUAYA | — |
| 18141009 | GENETIC SCREENING TO DETERMINE HEALTH RISKS ASSOCIATED WITH INTERACTING PHENOTYPES | WISE, OLIVIA M. | — |
| 18124670 | MITOCHONDRIAL PROBES FOR ENDOGENOUS CONTROL AND CONTAMINATION DETECTION | CLOW, LORI A | — |
| Art Unit | Apps |
|---|---|
| 1685 | 2 |
| 1687 | 2 |
| 3682 | 1 |
| 1682 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19362171 | SYSTEMS AND METHODS FOR PROVIDING TEST RESULTS OF GENE SEQUENCING DATA ON A RECURRING BASIS | EZEWOKO, MICHAEL I | 3682 | §101§103 | Non-Final OA | — | Pending | Oct 17, 2025 |
| 18470759 | POLYCYSTIC KIDNEY DISEASE DIAGNOSIS AND TREATMENT BASED ON DETECTION OF PKD1/PKD2 VARIANTS | SITTON, JEHANNE SOUAYA | 1682 | §101§103§112 | Final Rejection | — | Pending | Sep 20, 2023 |
| 18244592 | ENRICHMENT OF GENETIC MATERIAL WITH UPSCALED COT-1 DNA QUANTITIES | PHAM, KHAI QUYNH TIEN | 1684 | §103 | Final Rejection | 8d overdue | Pending | Sep 11, 2023 |
| 18141009 | GENETIC SCREENING TO DETERMINE HEALTH RISKS ASSOCIATED WITH INTERACTING PHENOTYPES | WISE, OLIVIA M. | 1685 | §101§103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18136670 | REANALYSIS BASED ON VERSION MANAGEMENT | HILL, GRACELYN MARKHAM | 1685 | §101§103 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18124670 | MITOCHONDRIAL PROBES FOR ENDOGENOUS CONTROL AND CONTAMINATION DETECTION | CLOW, LORI A | 1687 | §101§103§112 | Non-Final OA | — | Pending | Mar 22, 2023 |
| 18102202 | DIFFERENTIATION OF COINFECTION FROM CONTAMINATION WITHIN GENETIC SAMPLES | ELKINS, BLAKE HARRISON | 1687 | §101§103§112DP | Non-Final OA | — | Pending | Jan 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHelix Inc. has 7 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Michael I Ezewoko has the most, with 1 of Helix Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
